Navigation Links
New possibilities for flu antiviral and vaccine research emerge from 'Spanish flu' virus

es that made the 1918 virus so exceptionally deadly. We wanted to identify the specific genes responsible for its virulence, with the hope of designing antivirals or other interventions that would work against virulent pandemic or epidemic influenza viruses," said Tumpey.

"Science is publishing this study because it provides information necessary for developing drugs and vaccines that could help prevent another global flu pandemic. We carefully considered the implications of publishing this research and concluded that the knowledge we're gaining to potentially protect public health far outweighs the risk of working with this virus," said Donald Kennedy, editor-in-chief of Science.

"We were comforted to learn that this also was the conclusion of Dr. Anthony Fauci of the U.S. National Institute of Allergy and Infectious Diseases, Dr. Julie Gerberding of the Centers for Disease Control and Prevention, and Dr. Amy Patterson of the Office of Biotechnology Activities within the Office of Science Policy at the U.S. National Institutes of Health. Dr. Patterson is the spokesperson for the National Science Advisory Board for Biodefense (NSABB), which provides guidance and advice on the implications for dual use research and publication," Kennedy said.

To make the virus, the researchers used an approach called "reverse genetics," which involves transferring gene sequences of viral RNA into bacteria and then inserting combinations of the genes -- often after manipulating them -- into cell lines, where they combine to form a virus.

For the Science study, Jeffery Taubenberger of the Armed Forces Institute of Pathology provided the coding sequences for the eight Spanish flu genes to Christopher Basler, Peter Palese, Adolfo Garcíˇ­Sastre and their colleagues at the Mount Sinai School of Medicine. They spliced these sequences together with noncoding DNA from a closely related virus, since this portion of the genome wasn't available for the Spanish flu
'"/>

Source:American Association for the Advancement of Science


Page: 1 2 3

Related biology news :

1. New possibilities to fight pests with biological means
2. Three-dimensional, miniature endoscope opens new diagnostic possibilities
3. Heart failure: Intervention possibilities from imaging programmed cell loss
4. The quest for an effective HIV vaccine presents new possibilities, challenges
5. Novel antiviral technology inhibits RSV infection in mice
6. Biota makes major antiviral discovery
7. The reason why antiviral therapy cant annihilate HIV infection, and what to do about it
8. Bird flu -- Call for antiviral drugs to be shared
9. Research advances quest for HIV-1 vaccine
10. A much-needed shot in the arm for HIV vaccine development
11. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
Post Your Comments:
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/7/2014)... Researchers led by Dr. Debra Auguste, associate professor, ... at The City College of New York, have ... treatment for one of the most aggressive forms ... (TNBCs) have a high mortality rate owing to ... effective therapeutic options. However, Professor Auguste,s team, discovered ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... Researchers have long known that humans lack a key enzyme ... even plants -- that reverses severe sun damage. For ... at the atomic level to repair sun-damaged DNA. The ... prevention. In the early online edition of the journal ...
... Eeva Karjalainen, of the Finnish Forest Research Institute, Metla, "feel ... not many of us know that there is also scientific ... and other natural, green settings can reduce stress, ... Forest visits may also strengthen our immune system by increasing ...
... (SACRAMENTO, Calif.) A shared decision-making process would assist ... challenging and controversial choices presented when infants are born ... are being considered for elective corrective surgery, a new ... instances in which infants are born with conditions that ...
Cached Biology News:Researchers discover how key enzyme repairs sun-damaged DNA 2Study recommends that parents, physicians share decisions in sex development disorder surgery 2Study recommends that parents, physicians share decisions in sex development disorder surgery 3Study recommends that parents, physicians share decisions in sex development disorder surgery 4
(Date:11/28/2014)... (PRWEB) November 28, 2014 The report ... for all the important sub-segments of the market, in ... It maps the growth rates and market sizes for ... poised to witness rapid growth. It also includes analysis ... These company profiles include the financial performances, product portfolios, ...
(Date:11/27/2014)... 2014 First articles published ... Elsevier , a world-leading provider of scientific, ... to announce the launch of a new journal: ... The launch of Extreme Mechanics Letters ... forefront of applied sciences such as micro and nanotechnologies, ...
(Date:11/26/2014)... The report on the Global Smart Sensor Market in ... revenue forecasts and market trends. It expects the market ... to 2018. At the projected rate, the market is ... 2018. , Browse through the Global Smart Sensor Market ... market segmentation and in-depth analysis supported by a list ...
(Date:11/26/2014)... 2014 The announced sales of three healthcare ... looking to expand in non-healthcare areas, says Kalorama Information. ... research firm says that  Siemens is the third largest ... of the IVD market , with 5.5 billion in ... composition would likely affect IVD market shares.  ...
Breaking Biology Technology:Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 2Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 3Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 4Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 5Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... Inc. today announced that data from its phase 1/2 ... be highlighted in an oral presentation at the 50th ... in San Francisco, California, on December 9, 2008. , ... of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with ...
... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) today announced that ... update at the Piper,Jaffray Healthcare Conference in New York City ... Interested parties may access a ... of the BioMarin website, http://www.BMRN.com . A,replay of the ...
... JOLLA, Calif., Nov. 25 TorreyPines Therapeutics, Inc.,(Nasdaq: ... from Eli Lilly & Company,a reduction in certain royalty ... sales of TorreyPines, clinical-stage compounds NGX426 and tezampanel,should either ... rate will be reduced three percentage points and the ...
Cached Biology Technology:Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 2Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 3BioMarin to Present at the Piper Jaffray Healthcare Conference 2TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel 2